-
Mentor Capital Shares Accepted for DTC FAST Program for DWAC and DRS Handling
Cannabis M&A Leader Continues Steps Toward Larger Exchange Listing SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCQB: MNTR) reports its application to the Depository Trust Company to qualify Mentor shares for accelerated processing through the DTC Fast Automated Securities Transfer system has been approved. Because the DTC is strictly…
-
Mentor Capital Moves to OTCQB Venture Stage Market Feb 10th
Cannabis M&A Leader Continues Path Toward Larger Exchange Listing SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Pink: MNTR) reports it received confirmation from OTC Markets Group that on February 10, 2015, Mentor Capital will move up to the OTCQB venture stage marketplace for early stage and developing companies under the newly…
-
Mentor Capital CEO Discusses Marijuana and Ethics in Management Today Magazine
Ethics Help Businesses to Smoothly Advance Society and in the Cannabis Space are Rapidly Moving Beyond Illegality SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) is pleased to be on the cover in the “In Defense of Business Ethics” Fall 2014 edition of Management Today. Mentor CEO and article author, Chet Billingsley…
-
Mentor Capital Announces Second Stock Buyback
300,000 Shares to be Repurchased with 5% of Cash and Cash-like Assets SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) is initiating the repurchase of 300,000 shares of its currently outstanding common stock. The repurchase will be funded by the commitment of approximately 5% of the company’s cash and cash-like current assets which are specifically identified and…
-
Mentor Capital Provides Seed Finance for Nevada Cannabis Fund
Start-up Cash for Marijuana Focused Fund Provided through Mentor Subsidiary, Nevada Cannabis Ventures SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has provided seed funding to help launch an independently managed cannabis focused fund based in Nevada. The fund anticipates making marijuana related …
-
Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech…
-
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 101.7% during the first three quarters of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same…
-
Mentor Capital Enters Medical Marijuana Field to Combat Cancer Wasting
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has initiated investment in the Medical Marijuana market. “The ‘munchies’ are a godsend to cancer sufferers who just stop eating food that tastes like wood and leaves them nauseous,” explains Mentor CEO, Chester Billingsley. “In the days of clans and caves, elders…
-
Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now. The purpose of…
-
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the…